{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Keeton EK"],"funding":["NCI NIH HHS"],"pagination":["905-13"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC3916880"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["123(6)"],"pubmed_abstract":["Upregulation of Pim kinases is observed in several types of leukemias and lymphomas. Pim-1, -2, and -3 promote cell proliferation and survival downstream of cytokine and growth factor signaling pathways. AZD1208 is a potent, highly selective, and orally available Pim kinase inhibitor that effectively inhibits all three isoforms at <5 nM or <150 nM in enzyme and cell assays, respectively. AZD1208 inhibited the growth of 5 of 14 acute myeloid leukemia (AML) cell lines tested, and sensitivity correlates with Pim-1 expression and STAT5 activation. AZD1208 causes cell cycle arrest and apoptosis in MOLM-16 cells, accompanied by a dose-dependent reduction in phosphorylation of Bcl-2 antagonist of cell death, 4EBP1, p70S6K, and S6, as well as increases in cleaved caspase 3 and p27. Inhibition of p"],"journal":["Blood"],"pubmed_title":["AZD1208, a potent and selective pan-Pim kinase inhibitor, demonstrates efficacy in preclinical models of acute myeloid leukemia."],"pmcid":["PMC3916880"],"funding_grant_id":["CA77816","R01 CA077816"],"pubmed_authors":["Shen M","Lyne PD","Palakurthi S","Zheng X","Huszar D","Keeton EK","Chen H","Stone RM","Dillman KS","McEachern K","Kaur S","Platanias LC","Wang S","Wu A","Cao Y","Grondine MR","Lamb ML","Chen Y","Gibbons FD","Deangelo DJ","Dakin LA"],"additional_accession":[]},"is_claimable":false,"name":"AZD1208, a potent and selective pan-Pim kinase inhibitor, demonstrates efficacy in preclinical models of acute myeloid leukemia.","description":"Upregulation of Pim kinases is observed in several types of leukemias and lymphomas. Pim-1, -2, and -3 promote cell proliferation and survival downstream of cytokine and growth factor signaling pathways. AZD1208 is a potent, highly selective, and orally available Pim kinase inhibitor that effectively inhibits all three isoforms at <5 nM or <150 nM in enzyme and cell assays, respectively. AZD1208 inhibited the growth of 5 of 14 acute myeloid leukemia (AML) cell lines tested, and sensitivity correlates with Pim-1 expression and STAT5 activation. AZD1208 causes cell cycle arrest and apoptosis in MOLM-16 cells, accompanied by a dose-dependent reduction in phosphorylation of Bcl-2 antagonist of cell death, 4EBP1, p70S6K, and S6, as well as increases in cleaved caspase 3 and p27. Inhibition of p","dates":{"release":"2014-01-01T00:00:00Z","publication":"2014 Feb","modification":"2026-05-06T21:16:50.175Z","creation":"2026-04-07T22:21:42.123Z"},"accession":"S-EPMC3916880","cross_references":{"pubmed":["24363397"],"doi":["10.1182/blood-2013-04-495366"]}}